JPMorgan Chase & Co. Reduces Stake in Kymera Therapeutics, Inc. $KYMR

JPMorgan Chase & Co. lowered its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 7.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 192,699 shares of the company’s stock after selling 15,023 shares during the quarter. JPMorgan Chase & Co.’s holdings in Kymera Therapeutics were worth $10,907,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of KYMR. PNC Financial Services Group Inc. boosted its position in shares of Kymera Therapeutics by 506.6% in the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after acquiring an additional 770 shares during the period. Osaic Holdings Inc. boosted its holdings in Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after purchasing an additional 1,083 shares during the period. Bessemer Group Inc. grew its position in shares of Kymera Therapeutics by 652.0% during the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after purchasing an additional 815 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Kymera Therapeutics in the second quarter worth $73,000. Finally, Lazard Asset Management LLC bought a new position in shares of Kymera Therapeutics in the second quarter worth $116,000.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $83.52 on Friday. Kymera Therapeutics, Inc. has a fifty-two week low of $19.44 and a fifty-two week high of $103.00. The firm has a market cap of $6.82 billion, a price-to-earnings ratio of -22.70 and a beta of 2.20. The firm has a 50 day moving average price of $78.75 and a 200-day moving average price of $66.52.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The business had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. Kymera Therapeutics’s revenue for the quarter was down 60.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.88) EPS. As a group, equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Transactions at Kymera Therapeutics

In related news, Director Bruce Booth sold 229,809 shares of the firm’s stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $91.73, for a total transaction of $21,080,379.57. Following the transaction, the director directly owned 686,477 shares in the company, valued at $62,970,535.21. This trade represents a 25.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Nello Mainolfi sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $89.17, for a total value of $8,917,000.00. Following the completion of the sale, the chief executive officer owned 660,482 shares of the company’s stock, valued at $58,895,179.94. The trade was a 13.15% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 561,698 shares of company stock valued at $50,388,337. 16.01% of the stock is currently owned by corporate insiders.

Key Stories Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near‑term loss forecasts across Q1–Q4 2026 (small EPS improvements) and reiterated a Buy with a $134 target — this reduces short‑term downside expectations and supports investor interest. HC Wainwright note
• Positive Sentiment: Recent analyst target increases and bullish notes (including UBS coverage and other upgrades) signal renewed conviction in Kymera’s pipeline and cash runway; these reports are a constructive counterbalance to selling. UBS bullish note
• Positive Sentiment: Some outlets raised Kymera price targets (example: a recent note raising a target to $100), which can attract buyers and provide technical support. Price target update
• Neutral Sentiment: Technical/context: KYMR remains above its 200‑day moving average with elevated volatility (beta ~2.2); analyst consensus targets sit well above the current price, which can amplify both rallies and pullbacks. Market data
• Neutral Sentiment: Institutional activity shows modest position changes among several managers; current flows are not large enough to decisively move the stock by themselves. Institutional holdings
• Negative Sentiment: Large insider selling: Director Bruce Booth sold 81,866 shares (~$7.38M at ~ $90), a substantial, visible transaction that can be perceived as profit‑taking and pressuring the stock. Booth Form 4
• Negative Sentiment: Multiple senior executives (CFO, COO and others) disclosed sales across March 2–4, trimming positions by a few percent each—these repeated insider sales amplify short‑term negative sentiment despite company‑level explanations (e.g., diversification or tax/liquidity needs). Insider filings
• Negative Sentiment: Recent quarterly results (Feb. 26) showed an EPS miss and steep revenue decline year‑over‑year, which remains a fundamental drag on the stock until upcoming clinical milestones or revenue inflection points arrive. Earnings report

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on KYMR shares. Leerink Partners lifted their price objective on Kymera Therapeutics from $70.00 to $118.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Stephens lifted their price target on Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research report on Monday. HC Wainwright upped their price objective on shares of Kymera Therapeutics from $84.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Mizuho lifted their target price on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the company an “outperform” rating in a research report on Thursday, December 11th. Finally, Citigroup boosted their price target on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.50.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.